PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
38.68%
Cash & equivalents yoy growth below half of RVPH's 95.93%. Michael Burry would question if the firm faces a liquidity squeeze. Check for rising debts or negative cash flow.
No Data
No Data available this quarter, please select a different quarter.
38.68%
Below half of RVPH's 95.93%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
42.26%
0.5-0.75x RVPH's 72.84%. Martin Whitman might see risk if this hampers near-term financial flexibility.
101.21%
Higher PP&E (Net) Growth compared to RVPH's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
101.21%
Higher Total Non-Current Assets Growth compared to RVPH's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
42.36%
0.5-0.75x RVPH's 64.40%. Martin Whitman worries about slower asset growth than competitor. Is it strategy or constraint?
-44.89%
Less than half of RVPH's 5.25%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
146.14%
Exceeding 1.5x RVPH's 8.21%. Michael Burry suspects ballooning short-term obligations vs. competitor.
112.59%
Above 1.5x RVPH's 4.94%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
112.59%
Above 1.5x RVPH's 4.83%. Michael Burry sees a potential leverage warning sign.
-89.62%
Less than half of RVPH's 45.49%. David Dodd sees fewer share issuances vs. competitor.
-9.70%
≥ 1.5x RVPH's -3.55%. David Dodd sees higher yoy retained profits than competitor.
98.99%
Higher AOCI Growth compared to RVPH's zero value, indicating worse performance.
100.73%
Higher Other Stockholders' Equity Items Growth compared to RVPH's zero value, indicating worse performance.
-358.06%
Below half RVPH's 89.71%. Michael Burry sees potential underperformance in building shareholder capital.
42.36%
0.5-0.75x RVPH's 64.40%. Martin Whitman sees underexpansion or possible missed opportunities.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-34.72%
Less than half of RVPH's -102.37%. David Dodd sees better deleveraging or stronger cash buildup than competitor.